GABARAPL1 and lung adenocarcinoma: In breast cancer, neuroblastoma, hepatocellular carcinoma, and lung adenocarcinoma, higher expression levels of GABARAPL1 correlate with reduced risk of tumor metastasis and improved patient survival rates.